Apalutamid for treatment of nonmetastatic castration-resistant prostste cancer – case study
نویسندگان
چکیده
A special form of prostate cancer is non-metastatic castration-resistant cancer. Patients with this have rising prostate-specific antigen and castrate testosterone levels, no radiological findings metastatic disease on computed tomography bone scan. The phase III trials demonstrated apalutamide, darolutamide or enzalutamide to be associated a significantly longer median metastasis-free survival. featured description presents one case man castration- resistant who was treated apalutamide.
منابع مشابه
Nonmetastatic Castration-Resistant Prostate Cancer
After the introduction of prostate cancer screening with the prostate-specific antigen (PSA) test, we have witnessed a dramatic stage migration. As a result, an increasing number of patients are diagnosed at earlier stages and receive local treatments including surgery or radiation. When these local treatments fail by the definition of increasing PSA levels, patients are usually treated with an...
متن کاملOptimal treatment for castration-resistant prostate cancer
*KURAに登録されているコンテンツの利用については,著作権法に規定されている私的使用や引用などの範囲内で行ってください。 *著作権法に規定されている私的使用や引用などの範囲を超える利用を行う場合には,著作権者の許諾を得てください。ただし,著作権者 から著作権等管理事業者(学術著作権協会,日本著作出版権管理システムなど)に権利委託されているコンテンツの利用手続については ,各著作権等管理事業者に確認してください。 Title Optimal treatment for castration-resistant prostate cancer Author(s) Izumi, Kouji; Namiki, Mikio Citation Asian Journal of Andrology, 16(3): 498 Issue Date 2014-05 Type Journal Artic...
متن کاملRadium-223 for the treatment of castration-resistant prostate cancer
The vast majority of patients with metastatic castration-resistant prostate cancer (mCRPC) develop bone metastases. Bone metastases are a source of significant morbidity and affect quality of life in these patients. Several bone-targeting agents are approved for the treatment of bone metastases in prostate cancer, including bisphosphonates, denosumab, and radiopharmaceuticals. Radium-223 is a n...
متن کاملA Systematic Review of Clinical Practice Guidelines for Castration-Resistant Prostate Cancer
Cancer constitutes a huge burden on societies in countries with any level of economic development. Prostate cancer is the first most diagnosed cancer of men in developed countries and the forth one in developing countries in terms of incidence rate. It is also the third incident cancer of men in Iran along with a prevalence of about 10,000 cases. Castration-resistant prostate cancer (CRPC) is a...
متن کاملEnzalutamide for the treatment of metastatic castration-resistant prostate cancer
In recent years, several nonhormonal and hormonal agents, including enzalutamide, have been approved for the treatment of metastatic castration-resistant prostate cancer (CRPC) on the basis of improved overall survival in prospective clinical trials. The incorporation of these agents has revolutionized the treatment of CRPC but has also raised the question of what is the ideal sequence of admin...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: OncoReview
سال: 2023
ISSN: ['2082-8691']
DOI: https://doi.org/10.24292/01.or.131319323